Disease · MONDO_0001315

orthostatic intolerance

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. orthostatic intolerance. Diseases, record MONDO_0001315. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001315

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: orthostatic intolerance; Open Targets
Open Targets ID: MONDO_0001315; Open Targets
Other names: POTS, cardiovascular malfunction arising from mental factors, irritable heart, neurocirculatory asthenia, postural orthostatic tachycardia syndrome, postural tachycardia syndrome, soldiers heart; Open Targets
Disease Ontology: DOID:11569; Disease Ontology
MeSH: D009449; MeSH
Highest stage of its drugs: Phase 3, for 2 of its 40 drugs, from ClinicalTrials.gov; Open Targets

Drugs40

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
HUMAN IMMUNOGLOBULIN G	CHEMBL1201599		Phase 3	ClinicalTrials.gov	3	3	0	Drugs and targets
FLUVOXAMINE	CHEMBL814	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
DROXIDOPA	CHEMBL2103827	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
IVABRADINE	CHEMBL471737	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
2-(AMINOMETHYL)PHENOL	CHEMBL155572	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
EFGARTIGIMOD ALFA	CHEMBL4297551	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
FERRIC CARBOXYMALTOSE	CHEMBL2108597		Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
FERRIC OXYHYDROXIDE	CHEMBL4802224	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
FERROUS SULFATE	CHEMBL1200830	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 40

See all 40 drugs

Targets87

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRB1	Adrenergic receptor	4	Adrenergic receptor agonist; Beta-1 adrenergic receptor antagonist	Phase 2	https://conductscience.org/library/genes/153	Drugs and targets
ADRA2A	Adrenergic receptor	3	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist	Phase 2	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor	3	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist	Phase 2	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor	3	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist	Phase 2	https://conductscience.org/library/genes/152	Drugs and targets
ADRA1A	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist	Phase 2	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist	Phase 2	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist	Phase 2	https://conductscience.org/library/genes/146	Drugs and targets
ADRB2	Adrenergic receptor	2	Adrenergic receptor agonist; Beta-2 adrenergic receptor antagonist	Phase 2	https://conductscience.org/library/genes/154	Drugs and targets
ADRB3	Adrenergic receptor	2	Adrenergic receptor agonist; Beta-3 adrenergic receptor agonist	Phase 2	https://conductscience.org/library/genes/155	Drugs and targets
CHRNA3	Neuronal acetylcholine receptor; alpha3/beta4	2	Neuronal acetylcholine receptor; alpha3/beta4 antagonist; Neuronal acetylcholine receptor; alpha3/beta4 negative allosteric modulator	Phase 1/2	https://conductscience.org/library/genes/1136	Drugs and targets

1 to 10 of 87

See all 87 targets

Trials24

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05918978	Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS	Phase 2	33	2025-10-23	Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome	EFGARTIGIMOD ALFA	Its record names the disease	ClinicalTrials.gov
NCT05096884	Post-Acute Sequelae of Coronavirus-19 (COVID-19) With Dyspnea on Exertion And Associated TaChycardia TrEatment Study	Early phase 1	14	2024-12-03	Tachycardia, Dyspnea, COVID-19	METOPROLOL SUCCINATE	Its record names the disease	ClinicalTrials.gov
NCT00770484	Effect of Exercise in OI	Not applicable	12	2015-07-09	Orthostatic Intolerance, Postural Tachycardia Syndrome	PROPRANOLOL	Its record names the disease	ClinicalTrials.gov
NCT03070730	Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist	Phase 1/2	8	2017-05-18	Postural Orthostatic Tachycardia Syndrome, Orthostatic Intolerance	ATENOLOL, DROXIDOPA	Its record names the disease	ClinicalTrials.gov
NCT01978535	Iron Sucrose in Adolescents With Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)	Phase 1/2	3	2017-11-17	Postural Orthostatic Tachycardia Syndrome	IRON SUCROSE	Its record names the disease	ClinicalTrials.gov
NCT06305780	RECOVER-AUTONOMIC Platform Protocol	Phase 2	381		Long COVID, Long Covid19, Long Covid-19	IVABRADINE	Its record names the disease	ClinicalTrials.gov
NCT05823896	ImPROving Quality of LIFe in the Long COVID Patient	Phase 2	219		Post-COVID-19 Syndrome, Long COVID, Long Covid19, COVID-19, POTS - Postural Orthostatic Tachycardia Syndrome, Post COVID-19 Condition, Post-COVID Syndrome, Post COVID-19 Condition, Unspecified, Postinfectious Inflammation, Postinfectious Disorder	NIRMATRELVIR, RITONAVIR	Its record names the disease	ClinicalTrials.gov
NCT06305806	RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)	Phase 2	181		Long COVID, Long Covid19, Long Covid-19	IVABRADINE	Its record names the disease	ClinicalTrials.gov
NCT00580619	Autonomic Nervous System and Chronic Fatigue Syndrome	Phase 1	170		Chronic Fatigue Syndrome, Orthostatic Intolerance, Postural Tachycardia Syndrome	METHYLDOPA, TILARGININE, TRIMETHAPHAN	Its record names the disease	ClinicalTrials.gov
NCT06366724	LIFT: Life Improvement Trial	Phase 2	160		ME/CFS, Long COVID, PASC	NALTREXONE, PYRIDOSTIGMINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 24

See all 24 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Efgartigimod-Efgartigimod vs Placebo-Efgartigimod: Number of Participants With ADAs Against Efgartigimod	1 of 20	1 of 13	33	NCT05918978	Trial comparisons
Efgartigimod-Efgartigimod vs Placebo-Efgartigimod: deaths from any cause	0 of 20	0 of 13	33	NCT05918978	Trial comparisons
Efgartigimod-Efgartigimod vs Placebo-Efgartigimod: serious adverse events	0 of 20	0 of 13	33	NCT05918978	Trial comparisons
Propranolol Then Placebo vs Placebo Then Propranolol: serious adverse events	0 of 8	0 of 4	12	NCT00770484	Trial comparisons
Iron Infusion vs Normal Saline Infusion: deaths from any cause	0 of 1	0 of 2	3	NCT01978535	Trial comparisons
Iron Infusion vs Normal Saline Infusion: serious adverse events	0 of 1	0 of 2	3	NCT01978535	Trial comparisons

Papers from its trials14

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
22174345	RESULT	1	PubMed
21906029	RESULT	1	PubMed
19687359	RESULT	1	PubMed
15911704	RESULT	1	PubMed
43000413	DERIVED	1	PubMed
41720282	DERIVED	2	PubMed
32673517	DERIVED	1	PubMed
29573263	DERIVED	1	PubMed
24721800	DERIVED	1	PubMed
24606242	DERIVED	1	PubMed

1 to 10 of 14

See all 14 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001315

GET https://conductscience.org/api/diseases/v1/MONDO_0001315/drugs?page=2

API reference For AI assistants